Please assess the completion status of the following clinical trial:

Trial Title: To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a primary diagnosis of schizophrenia~* History of at least 1 prior episode of acute schizophrenia in the 3 years preceding screening~* History of schizophrenia requiring continuous antipsychotic treatment for at least 1 years preceding screening~* Clinically stable at the time of entry defined by at least a 4 week period of stable symptoms~Key Exclusion Criteria:~* Have an uncontrolled, unstable clinically significant medical condition~* History of suicide attempt or significant violence to others in the past 2 years~* A substance-induced psychotic disorder or behavioral disturbance thought to be due to substance abuse~* Current substance abuse/dependence~* Concurrent psychiatric disorder other than schizophrenia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- asenapine (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).